umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity
Umeå University, Faculty of Medicine, Department of Clinical Microbiology, Virology.
Show others and affiliations
2012 (English)In: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 7, no 7, e40385- p.Article in journal (Refereed) Published
Abstract [en]

Recombinant adenoviruses are among the most promising tools for vaccine antigen delivery. Recently, the development of new vectors has focused on serotypes to which the human population is less exposed in order to circumvent preexisting anti vector immunity. This study describes the derivation of a new vaccine vector based on a chimpanzee adenovirus, Y25, together with a comparative assessment of its potential to elicit transgene product specific immune responses in mice. The vector was constructed in a bacterial artificial chromosome to facilitate genetic manipulation of genomic clones. In order to conduct a fair head-to-head immunological comparison of multiple adenoviral vectors, we optimised a method for accurate determination of infectious titre, since this parameter exhibits profound natural variability and can confound immunogenicity studies when doses are based on viral particle estimation. Cellular immunogenicity of recombinant E1 E3-deleted vector ChAdY25 was comparable to that of other species E derived chimpanzee adenovirus vectors including ChAd63, the first simian adenovirus vector to enter clinical trials in humans. Furthermore, the prevalence of virus neutralizing antibodies (titre >1:200) against ChAdY25 in serum samples collected from two human populations in the UK and Gambia was particularly low compared to published data for other chimpanzee adenoviruses. These findings support the continued development of new chimpanzee adenovirus vectors, including ChAdY25, for clinical use.

Place, publisher, year, edition, pages
2012. Vol. 7, no 7, e40385- p.
National Category
Microbiology in the medical area
Identifiers
URN: urn:nbn:se:umu:diva-57749DOI: 10.1371/journal.pone.0040385ISI: 000306406700026OAI: oai:DiVA.org:umu-57749DiVA: diva2:545418
Available from: 2012-08-20 Created: 2012-08-14 Last updated: 2017-12-07Bibliographically approved

Open Access in DiVA

fulltext(673 kB)135 downloads
File information
File name FULLTEXT01.pdfFile size 673 kBChecksum SHA-512
a2a3ca85c59a353a71bc002c0dc2a4003722eff267a78b02ab419897072a5737077402ab2be3dfd628073e6321c2f46b0547143974f419df8c248c16c5ffbe75
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Authority records BETA

Wadell, Göran

Search in DiVA

By author/editor
Wadell, Göran
By organisation
Virology
In the same journal
PLoS ONE
Microbiology in the medical area

Search outside of DiVA

GoogleGoogle Scholar
Total: 135 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 98 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf